Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Baraclude in Chronic Hepatitis B
NCT03083821Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of entecavir in Chronic Hepatitis B (CHB), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration up to 24 hours, Time of Maximum Observed Plasma Concentration up to 24 hours and 4 more. Started May 2017; status: completed.
02
Drugs
entecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03083821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083821.